ams-OSRAM AG (AMS) Guides Q4 Revenue to EUR 750–850M

ams-OSRAM AG reported Q3 2023 revenue of EUR 829M, up 3% sequentially but down 3% year-on-year. The company expects Q4 2023 revenue of EUR 750–850M and an adjusted EBITDA margin of 16.0% ± 1.5 percentage points. The guidance comes amid portfolio reshaping and semiconductor growth.

Original reporting
Published Nov 13, 2026, 6:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ams-OSRAM AG (AMS) Guides Q4 Revenue to EUR 750–850M — source image
Decision brief

The 30-second read

$AMSNeutralMed
01

Why it matters

The guidance sets expectations for FY27 free‑cash‑flow and may drive short‑term price movement.

02

Market read

First disclosure of Q4 guidance provides new data for valuation models and may influence sector peers.

03

What to watch

Potential impact of ongoing divestments and portfolio reshaping on future cash flow.

Relevance 7/10Novelty 7/10Timing: Q4 guidance release

Background

ams‑OSRAM AG released a quarterly update with Q4 revenue and margin guidance, noting core semiconductor growth and divestment effects.

Company-level read

Ticker impact

$AMSNeutralHigh confidence
Context

Company provided Q4 2026 revenue guidance of EUR 750–850M and adjusted EBITDA margin guidance.

Expected impact

potential downside pressure if guidance falls short of market expectations

Evidence & confidence

Guidance is the first public disclosure of Q4 expectations; traders will adjust valuations accordingly.

Market effects

Guidance may affect the broader semiconductor and optoelectronics sector as peers compare outlooks.

European semiconductor market sentiment could shift based on the guidance.

Limited to investors tracking mid‑cap semiconductor stocks.

Counterpoint

If the market overreacts to the lower end of the range, a bounce could occur on later positive news.

Key entities

  • ams‑OSRAM AG

    German semiconductor and optoelectronics manufacturer.

Related articles

$AMSHighAI 8/10

Why is ams OSRAM stock sliding today?

ams OSRAM (AOS) shares fell 6.6% to CHF 15.67 after Q3 2026 results and Q4 guidance. Q4 revenue forecast (€750M-€850M) and adjusted EBITDA margin (16% ±1.5%) missed expectations. Q3 revenue (€829M) beat consensus, but adjusted EBITDA dropped 19% YoY. The stock declined on cautious outlook and margin compression.

$AMSMedAI 8/10

Ams OSRAM Swings To Q3 Profit On A Disposal Gain, Guides Q4

ams-OSRAM AG reported a Q3 net profit of €319M (€2.97/share) vs. a loss of €28M (€0.28/share) a year earlier, driven by a disposal gain. Revenue fell 3% to €829M. Adjusted EBITDA dropped to €135M. The company expects Q4 revenue of €750M-€850M and an adjusted EBITDA margin of 16.0% ±1.5%.

$AMSMed

American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results

AMERICAN SHARED HOSPITAL SERVICES (AMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results Third Quarter Revenue Increased 6% to $7.6 Million; Direct Patient Services Revenue Increased 14% Nine-Month Revenue Increased 14% to $23.1 Million; Direct Patient Services

$AMSMed

Amadeus IT Group 9-Month Revenue Rises

Amadeus IT Group reported a 3.7% revenue increase to EUR 5.075 billion for the first nine months of fiscal 2026. Net income fell slightly to EUR 1.081 billion, while adjusted profit rose to EUR 1.147 billion. CEO Luis Maroto expects 2026 outlook to be met, likely at the lower end, due to Middle East impacts.

$AMSMed

American Shared Hospital Services Q2 Net Loss Widens to $514,000 Despite Revenue Growth – Minichart

American Shared Hospital Services (NYSE American: AMS) reported a Q2 2026 net loss of $514,000, or $0.07 per diluted share, widening from a $280,000 loss a year earlier, despite revenue rising 19.2% to $8.43 million. Direct patient services drove growth, while gross profit and operating loss worsened. Cash rose to $6.511 million at June 30, 2026, and the company later arranged financing with Fifth Third Bank.